Bridge-Enhanced (TM) ACL Repair Clinical Trial

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the ACL Program

  • 617-355-3501
  • International: +1-617-355-5209
  • Locations

Every year, approximately 400,000 anterior cruciate ligament (ACL) injuries occur. ACL reconstruction surgery is one of the most common orthopedic procedures in the United States. Unlike other ligaments, the ends of a torn ACL do not reconnect. During an ACL reconstruction, an orthopedic surgeon removes the ends of the torn ACL and replaces them with a graft, usually from two of the patient’s hamstring tendons. Although most patients are able to return to sports, the ACL re-tear rate can be as high as 20 percent for teens. Up to 80 percent of patients develop arthritis 15 to 20 years after surgery.

What is bridge-enhanced (TM) ACL repair?

The new technique, bridge-enhanced™ ACL repair (BEAR™), uses stitches and a bridging scaffold (a sponge injected with the patient’s blood) to stimulate healing of the torn ACL. This tissue engineered scaffold has been studied with over 20 years of research at Boston Children's Hospital and its use in patients is currently regulated closely by the FDA. Boston Children's Hospital is the only place where the bridge-enhanced ACL repair procedure is performed. There are no other clinics or hospitals that have this device or can truthfully offer this technique to patients.

What are the differences between ACL reconstruction and bridge-enhanced (TM)
ACL repair?

ACL reconstruction:

•   standard care for ACL tears, proven to be safe and effective
•   requires incision to harvest the graft; other work done arthroscopically
•   requires graft harvest of patient’s own tendon
•   remaining ACL tissue is removed

Bridge-enhanced ACL repair (BEAR) at Boston Children's Hospital

Bridge-enhanced (TM) repair:

•   experimental use of a bridging scaffold with some unknown risks and benefits
•   requires incision to insert scaffold; other work done arthroscopically
•   no graft harvest of patient’s tendon
•   remaining ACL tissue is preserved

Learn more about the BEAR (TM) clinical trial

The BEAR(TM) II trial is now fully enrolled. To learn more about the study, please email

Boston Children’s is so much more than a hospital—it’s a community of researchers, clinicians, administrators, support staff, innovators, teachers, patients and families, all working together to make the impossible possible. ”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337